Aerovate Therapeutics Q4 2023 GAAP EPS $(0.74) Misses $(0.70) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aerovate Therapeutics reported a Q4 2023 GAAP EPS of $(0.74), missing the consensus estimate of $(0.70) by 5.71%.
March 25, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aerovate Therapeutics reported a Q4 2023 GAAP EPS of $(0.74), missing the consensus estimate of $(0.70) by 5.71%.
Missing the consensus earnings estimate typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100